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1. Introduction 
The aim of this chapter is to present a revised overview of small and large animal 
transfusion medicine based on a review of the veterinary literature. Blood transfusion has 
become more performable in small and large animal practice. By donor selection and the 
availability of blood component substitutes, usage of the blood products improved. The use 
of blood component therapy safely needed knowledge of blood groups, antibody prevalence 
and the impact of blood groups on veterinary transfusion medicine. Animal blood 
transfusions antibodies against blood group antigens also play a role. In addition 
knowledge of the means to decrease the risk of adverse reactions by using proper donors 
and screening assays that simplify detection of serological incompatibility is important. The 
clinical significance of blood group antigens in veterinary medicine is generally in the areas 
of transfusion reactions and neonatal isoerythrolysis (NI). This chapter includes an update 
on canine and feline, horse, donkey, cattle, sheep, gaot, pig, llama and alpaca blood groups 
and known blood incompatibilities, donor selection and blood collection, storage of blood 
components, available equine blood products and indications for transfusion, whole blood 
(WB) and blood product transfusion in ruminants and camelids, blood component and 
blood substitute therapy, administration, and adverse reactions in small and large animal 
blood transfusion.  
2. Blood types in dogs and cats 
Blood types are classified according to specific antigens on the surface of erythrocytes. 
Platelets, leukocytes, and body tissues and fluids may also consists of erytrocyte antigens. 
[1]. In immunogenicity and clinical significance these antigens can differ. They can serve as 
markers of disease in some cases and taking part in recognition of self. The clinical 
significance of blood group antigens is generally noted in transfusion reactions and neonatal 
isoerythrolysis (NI) in veterinary medicine [2]. These antigens can characteristically trigger a 
reaction caused by circulating anti-erythrocyte antibodies in the opposite host or donor. 
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These antibodies can occur naturally. Also they can be induced by a previous transfusion. 
Interaction leads to the destruction by hemolysis of red blood cells (RBCs). This is one of the 
severe and potentially life-threatening situation. [3].  
The dog erytrocyte antigen types or blood types are categorized by the DEA (Dog 
Erythrocyte Antigen) system. DEA 1.1, 1.2, and 1.3 are termed A system. There are also DEA 
3, DEA 4, DEA 5, DEA 6, DEA 7 and DEA 8. [2]. In the United States the incidence of DEA 
1.1 is approximately 45% and DEA 1.2 is 20% [4]. DEA 1.3 is common in German shepherd 
dogs and has been reported only in Australia [5]. Frequency of DEA 1.1 in Kangal Dog was 
found as 61.1% in Turkey [6]. In Croatia where the closest data studied the rate was 66.7% 
[7]. The rate was also 56.9% in Portugal [8] and 55% in Japan [9]. Approximately 60 % of the 
canine population is in DEAs 1.1 and 1.2 group. DEA 1.1 is the strongest antigen in the dog. 
Two membrane proteins of 50 and 200 kD has been identified by a monoclonal antibody to 
DEA 1.1 using immunoprecipitation techniques. [10]. Presenting in a single band DEA 1.2 
has been found to be an 85-kD protein [11].  
DEA 1.1 is the most antigenic group in respect to transfusion medicine. Little is investigated 
about DEA 3, 4, 5 and 7 in comparison to DEA 1.1. In literature, the frequency of DEA 3 is 
lower in comparison to DEA 1.1 blood type. In the United States it is determined that 
approximately 6% of the general dog population is DEA 3 positive [12]. This rate is reported 
as 13% in Brazil [13]. In Turkey, DEA 3 is most found blood type in the Kangal Dog [6]. In 
the canine blood groups DEA 4 is the most common type. In USA, it is indicated that overall 
98% of the general dog population have DEA 4 blood [12]. In Brazil, all dogs blood type 
were positive for DEA 4 [13]. The molecular weight of DEA 4 present in a single band has 
been found to be 32 to 40 kD using immunoprecipitation techniques [11].  
In the United States typing sera can be commercially obtained only for DEA 1.1, 1.2, 3, 4, 5, 
and 7 [4]. In Brazil a report studied on German shepherd dogs determined that 14% of the 
dogs were positive for DEA 5 and 8% were positive for DEA 7 [13]. The frequency of DEA 5 
and 7 positive dogs was 55.5% and 71.7% respectively in Turkey [6]. Also, DEA 7 may cause 
an antibody response in dogs that lack it. A system of nomenclature about antigen Tr has 
described. The Tr antigen system is a 3-phenotype, 6-genotype system [14]. The molecular 
weight of DEA 7 present in 3 distinct bands has been found to be 53, 58, and 63 kD by using 
immunoprecipitation techniques [11].  
An exact definition of a canine universal donor is not agreed among veterinary transfusion 
experts. Well excepted description of the universal donor is that a dog negative for DEA 1.1, 
1.2, DEA 3, DEA 5, DEA 7, and positive for DEA 4. It is difficult to find DEA 4 negative dog 
because 98% of all dogs are positive for DEA 4. Thus there is a very little chance to influence 
donor selection. If the dog is DEA 7 positive, some other experts do not exclude it from the 
donor pool [15]. In most populations the incidence of DEA 4 blood type is more than 98% 
[16]. Because of this in transfusion medicine these dogs are the best candidate for being a 
donor. If other donors are known to be compatible with the recipient they can also be 
utilized [17]. DEA 3, 5 and 7 negative dogs have naturally occurring antibodies to DEA 3, 5 
and 7 positive red cells. However during the first transfusion these blood groups do not 
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possess a major transfusion reaction [4]. In Turkey, the most common blood types were 
DEA 1.1, 4 and 7. Because all Kangal dogs have DEA 4 positivity it does not seem to be 
important in respect to transfusion medicine. The prevalence and antigenic properties of 
DEA 1.1 and 7 are significantly important. If unmatched transfusion is performed in Turkish 
Kangal dogs they can constitute acute hemolytic transfusion reactions [6]. Dogs with DEA 
1.1 or 1.2 are called group A positive. Adversely, dogs do not have DEA 1.1 or 1.2 are called 
group A negative [1].  
A blood group system described as N-acetylneuraminic acid and N-glycolylneuraminic acid 
present on gangliosides (hematosides) of the RBC membrane in Japan [18]. It is referred as 
the D system. This system is consist of two antigens, D1 and D2, with phenotypes, D1, D2, 
and D1D2. The D1 and D2 antigens are codominanat factors. Anti-D1 is identical to anti-
DEA3. The importance of this system in transfusion medicine pointed out by transfusion of 
D2 type blood into a D1 type patient, or of D1 type blood into a D2 type patient consistently 
cause severe acute transfusion reactions [19, 20]. RBCs of some dogs designated as type C at 
titre sup to 128 are aglutinated rather than lectin extracted from seeds of Clerodendron 
tricotomum. Type C is completely negative for other dogs. C system was compared to the 
DEA system and determined to be different [10, 19, 21]. Specific IgG alloantibodies in 
previously sensitized Dalmatian dog by blood transfusion is described as the Dal blood 
type. The frequency is not known. Typing sera for this antigen also is commercially not 
available [2, 22, 23].  
Three blood types are described in the feline AB blood group system and mik group system. 
In cats a new blood group defined as Mik. It is named after the alloantibody identified in the 
first blood donor cat, Mike. In three cats that had not previously received transfusions Mik 
antibodies were detected. They are defined as a cause of incompatibilities between donor 
and recipient blood that are not related to the AB blood group system [24].  
The phenotypes type A, type B, and type AB are occured. A null phenotype is not exist. The 
most common blood type is Type A. Type B is less common. Type AB is rare [2, 25]. Type B 
is indicated in Australia (26.3%), and Greece (20.3%) ([26] , [27] ). In large studies of both 
pedigree and non-pedigree cats in the USA distribution of type AB cats is demonstrated to 
be rare (0.14%) ([28] ). Type AB were 0.4% in Australia (([26]). In Scotland the incidence of 
AB cats is 4.4% ([29] ). 
Type B is indicated in Australia (26.3%), and Greece (20.3%) ([26, 27]. In large studies of both 
pedigree and non-pedigree cats in the USA distribution of type AB cats is demonstrated to 
be rare (0.14%) [28]. Type AB were 0.4% in Australia [26]. In Scotland the incidence of AB 
cats is 4.4% [29]. 
In Turkey, 60 % of Van cats and 46.4 % of Angora cats are type B [30]. And 220 (73.1%) 
nonpedigree domestic cats had type A blood, 74 (24.6%) had type B and seven (2.3%) had 
type AB [31] in Turkey. Except type AB group, cats have naturally occurring alloantibodies. 
It is known that cats have naturally occurring alloantibodies (isoantibodies) against the 
blood type they are lacking. Because of this to prevent blood incompatibility reactions in 
cats feline blood typing is important in clinical practice. Blood type incompatibility can 
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especially result in two fatal reactions. The first is acute haemolytic transfusion reactions, 
occur particularly in cat transfused with type A blood [32]. Feline neonatal isoerythrolysis 
(NI) is the second incompatibility reaction. It occurs when type A or AB kittens born to type 
B queens are nursing. Naturally occurring anti-A alloantibodies result in blood 
incompatibility reaction in the type B queen’s colostrum and milk [25, 30].  
Cats constitute non-self antibodies in contrast to dogs. As a result of this non-self antibodies 
potentially fatal antibody-mediated reactions can occur towards non-self red blood cells. 
Nearly 20% of type A cats have anti-B antibodies. These antibodies are usually weak. All 
type B cats have strong anti-A antibodies. In contrast AB cats do not have alloantibodies 
[32]. In previously unsensitized cats naturally occuring isoantibodies are responsible for 
transfusion reactions. Nearly all type B cats have highly titered anti-A agglutinins and 
hemolysins. RBCs can be destructed rapidly in type B cats taking type A blood. In type B 
cats the high titres of naturally occurring anti-A antibodies cause rapid intravascular 
destruction of transfused type A red blood cells [33]. This can be mediated by IgM, 
complement fixation and the release of potent vasoactive compounds. As a result of this 
shock can develop usually due to possessed antibodies towards the transfused RBCs [3, 34]. 
This can cause severe transfusion reaction and death even if as little as 1 ml of type A blood 
is administered to a type B-cat [2, 35]. Because of their endotheliochorial placenta newborn 
kittens have no alloantibodies. Nevertheless colostral transfer of immunoglobulin (Ig) G and 
a small amount of IgM occurs. Neonatal isoerythrolysis develops in cats. It is one of the 
cause of the fading kitten syndrome. Kittens that are type A or AB and those that are born to 
type B queens are at risk.  In affected kittens Clinical sings can range from unapparent, to 
severe hemolytic anemia with hemoglobinuria, icterus, and death [1, 36, 37, 38].  
3. Transfusion therapy 
Packed red blood cells (pRBCs) and fresh frozen plasma (FFP) are components generally 
provided for canine transfusions. If processed at once, 1-4 each unit (450 mL) of whole blood 
can be seperated into 1 unit of pRBCs and 1 unit of FFP. It is difficult to prepare components 
from a small volume of blood. Because of this cat blood transfusions are usually 
administered as fresh or stored whole blood. If patients requires specific components like 
pRBCs and FFP, in this case whole blood can be separated into them [39]. 
In veterinary medicine, red blood cell transfusions are used more frequent recently. They 
are the integral part of lifesaving. They are used in critically ill as advanced treatment. 
Situations required transfusions include life-threatening anemia from acute hemorrhage or 
surgical blood loss, hemolysis from drugs or toxins, immune-mediated diseases, severe 
nonregenerative conditions, and neonatal isoerythrolysis [40]. 
Indications of red blood cell transfusions are in the treatment of anemia caused by 
hemorrhage, hemolysis, or ineffective erythropoiesis. Oxygen is poorly soluble in plasma. 
Because of this oxygen in blood is mostly carried by hemoglobin (Hgb). In anemic patient, 
RBC transfusions increase the oxygen-carrying capacity. Therefore inadequate delivery of 
oxygen to tissues with consequent tissue hypoxia are prevented or treated [41]. 
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The treatment of severe anemia caused by hemorrhage, hemolysis, ineffective 
erythropoiesis, auto-immune hemolytic anemia, or neoplasia is primary indication for blood 
transfusion. Lethargy and altered mentation, increased respiratory effort, pale mucous 
membranes and tachycardia are the clinical signs of anaemia. The body carry out a number 
of adaptive responses physiologically, to maintain carrying of oxygen to the tissues [42, 43]. 
The solution of oxygen in plasma is weak. Because of this hemoglobin (Hgb) carries 
approximately whole oxygen in blood [41]. The decision to conduct a RBC transfusion is 
generally based on a measurement of the patient's packed cell volume (PCV), hematocrit 
(Hct) or Hgb concentration (Hgb) and especially on clinical evaluation of the patient [41]. 
Clinically animals should be evaluated individually. Generally when the hematocrit is less 
than 10%, the treatment of anemia is transfusion. However, animals with acute-onset 
anemia usually require transfusion before their hematocrit decreases to 15%. This contrasts 
with the situation in animals with chronic anemia. Other indications for transfusion are 
hypovolemia, thrombocytopenia, clotting factor deficiency, and hypoproteinemia [1]. 
Electrocardiographic signs of myocardial ischaemia are similar to those identified in human 
patients with myocardial infarction. It can ocur with anemia [44]. 
The usage of administration of FFP are for the treatment of a single or multiple clotting 
factor deficiency, vitamin K deficiency or antagonism, surgical bleeding or where a massive 
transfusion is required [45]. Hypoalbuminaemia and coagulopathies especially due to liver 
disease are the main reported indications for FFP transfusions in cats [46].  
Stored blood is more than 8 hours old. The length of storage depends on the 
anticoagulant/preservative solution used. It varies from 48 hours for 3.8% sodium citrate (no 
preservative) to 4 weeks for CPD-A1 (citrate, phosphate, dextrose, and adenine). Acid citrate 
dextrose (ACD), citrate phosphate dextrose (CPD and CP2D), and citrate 
phosphatedextrose-adenine (CPDA-1) are mostly used as preservatives. The viability of 
RBCs is provided by the added dextrose, phosphate, and adenine. Due to the preservative 
used, the storage can extend up to 3 to 5 week ([3, 41, 47]. 
In patients that are hypothermic or receiving large volumes of blood, refrigerated RBC 
products should be prewarmed to temperatures between 22°C and 37°C immediately before 
transfusion. In the routine practice of RBC products to normovolemic anemic patients, 
refrigerated blood components do not need warming before transfusion. Warming may 
accelerate the deterioration of stored RBCs and may cause rapid growth of contaminating 
microorganisms [48].  
In clinical practice advances in safety of blood transfusion is important in preventing 
transfusion-transmitted infections (TTI). The most frequent severe infectious outcome of 
transfusion has been known as bacterial contamination of platelets, with resultant sepsis in 
the recipient recently. Using automated or semi-automated blood culture devices, apheresis 
platelets and prestorage pooled platelets are most often tested [49]. 
Generally, before a blood transfusion is given to animals, blood typing and/or cross-
matching of the recipent and donor should be done to avoid the likelihood of a transfusion 
reaction. Also, ineffective therapy is caused by shortened survival of transfused mismatched 
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red cells. In order to prevent primary sensitization and risk of developing hemolytic disease 
in breeding females, cross-matching and/or blood typing is important. In general veterinary 
practise, blood typing for canine DEA 1.1 and for feline types A and B is applied [1].  
To decrease adverse reactions one sould pay attention to blood typing and crossmatching 
procedures as much as monitoring. There is always risk in blood transfusions. For this 
reason, they should be performed only when warranted. When taking history, previous 
transfusion therapy should be asked and in a history of previous transfusion therapy cross-
matching is necessary [1, 50].  
Depending on availability and indication for transfusion, whole-blood or blood-component 
therapy may be administered. RBCs, white blood cells (WBCs), platelets, all the coagulation 
factors, albumin and immunoglobulins constitute whole blood (WB) [51].  
In cats, fresh whole blood is the most common product used recently. Stored whole blood, 
packed red blood cells and fresh frozen plasma (FFP) are also given as transfusions [45]. 
The heavier cellular elements from the supernatant plasma are sedimented by centrifugation 
of whole blood sediments. Due to separation of blood collection within 8 hours all protein 
activity and concentration are maintained in the plasma. The obtained supernatant usually 
frozen. For subsequent transfusion, it is stored as fresh frozen plasma (FFP). In addition it 
can also processed to provide cryoprecipitate and cryosupernatant. It can also be transfused 
immediately as fresh plasma [52, 53]. Fresh frozen plasma have to be stored frozen at -30°C 
before used. Also it should be identified with the donor blood type, name and collection 
date. Samples thawed and not used sould discarded or stored in a fridge and used within 
12-24 h and should not be refrozen [43].  
Recently an ultra-purified polymerised bovine haemoglobin solution is the only 
commercially available alternative to red cell transfusion (Oxyglobin). It is not licensed in 
cats but it has been used in treatment of anaemia in cats and also in therapy of carbon 
monoxide poisoning [54, 55].  
Hemostatic protein deficiencies lead to hemorrhagic disorders and the treatment is done 
principally by plasma components [56]. In animals with von Willebrand disease (vWD) and 
hereditary coagulation factor deficiencies active hemorrhage is controlled by plasma 
components. Plasma components are also used for preoperative prophylaxis in these 
diseases [53].  
For preparation of plasma components sterile plastic bags are used. After that they are 
stored and transferred as frozen in individual boxes. Products have to be stored at -20°C or 
lower. Just before transfusion they warmed to 37°C in a water bath or incubator. Preferred 
route of administration is the intravenous transfusion of plasma components. If attempts at 
vascular access have failed, intraosseous transfusion can be used in emergency situations. 
When acut allergic reactions occur transfusion is stopped and antihistamines and/or short-
acting steroids are given [53, 57].  
Cats have antibodies to non-self blood types within the plasma. Because of this only type-
specific plasma should be administered to cats in contrast to dogs. Using one of the 
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commercially available systems whole blood can be separated into FFP and packed red cells 
if it is taken aseptically. The blood spun at 3800 rpm at 10˚C in a refrigerated centrifuge for 
12 mins. Using a plasma extractor the plasma is extracted and stored at –20°C [57].  
In hypoalbuminemic dogs and cats, human serum albumin has been used for therapeutic 
use [58]. 
3.1. Platelet transfusion 
Correction of coagulation by fresh platelets are shown by in vitro coagulation studies. 
Freshly collected platelets correct thrombocytopenia, control associated hemorrhage, and 
prevent death from bleeding. Hemorrhagic diathesis are prevented by platelet replacement 
for thrombocytopenia [59]. 
Severe thrombocytopenia or thrombopathia result in bleeding. Platelet transfusion is used 
for the control of this bleeding. In veterinary medicine platelet transfusion has been used 
rarely compared to red blood cell (RBC) and plasma transfusion. In dogs, reports related 
to platelet transfusion are generally associated with experimental hematopoietic stem cell 
transplantation. Platelet-rich blood products consist of fresh whole blood (FWB), platelet-
rich plasma (PRP) and platelet concentrate (PC). They are used for aggressive anticancer 
therapy and treating complex hematologic disorders. Centrifugation of whole blood 
constitute platelet-rich plasma (PRP) and centrifugation of platelet-rich plasma constitude 
platelet concentrates (PC). Platelet activation is induced by centrifugation so that the 
resuspension of the platelet pellet during PC preparation from dogs is difficult. The 
preparation efficiency of PC from dogs can be improved by addition of PGE1 in PRP 
before the centrifugation of PRP. Also therapeutic efficacy of the platelets are maintained. 
In 10-28 kg body weight dogs plateletpheresis has been used successfully. On the canine 
donor thrombocytopenia and hypocalcemia are the main adverse effects of 
plateletpheresis [60-62]. 
At room temperature (RT) (20-24°C), PRP and PC can be stored for 5-7 days with continuous 
or intermittent agitation. At RT FWB can be stored for up to 8 hours. The interest in freezed 
(4°C) storage of platelets is increasing because of the increased risk of bacterial proliferation 
at RT storage. Storage of human PRP and PC are limited to 5 days because of prevention of 
bacterial proliferation at room temperature [60- 63]. 
Platelet transfusions as with RBC and plasma components should be performed with 170 
µm filters standard blood administration sets. Transfusion sets which can bind platelets 
should be exempt from latex [60]. 
The most common reaction to PC are febrile reactions. The frequency is decreased by pre-
storage leukoreduction. In immunocompetent dogs receiving multiple transfusions, 
alloimmunization to platelet antigens occurs. Leukocyte reduction and ultraviolet B 
irradiation are recently accepted methods for preventing the development of platelet 
alloimmunization [64-66]. 
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Recently platelet cryopreservation are used to provide long-term storage and immediate 
availability of platelet products for transfusion. When fresh platelets are unavailable 
cryopreserved platelets can be activated in vitro and provide therapeutic benefit [63]. 
3.2. Granulocyte transfusion 
Granulocyte transfusion can be used as supportive therapy. It is used in patients with life-
threatening neutropenia caused by bone marrow failure or in patients with neutrophil 
dysfunction. Granulocyte transfusions is shown to be useful in treatment of infections in 
patients after treatment with high-dose chemotherapy. It is helpful especially in the 
chemotherapy associated with conditioning for hematopoietic stem cell transplant. By using 
granulocyte colony-stimulated factors higher doses of granulocytes for transfusion are 
produced. Thus recently the use of therapeutic granulocyte transfusion has been increased. 
The outcome of transfusion are effected by the type of infection being treated, the likelihood 
of recipient marrow recovery, and recipient alloimmunization [67]. 
In small animals therapeutic granulocyte transfusions have been used especially in 
experimental models of myelosuppression and neonatal sepsis. In clinical veterinary 
medicine they have been used rarely. Granulocytes can be used to identify the site of 
inflammation. Beside leukapheresis, centrifugation of FWB, with or without colloid-
facilitated sedimentation, may be used to isolate canine and feline buffy coats. Only 
sedimentation may also be used in the cat. At RT granulocytes are stored immobil for 24 
hours. The dose for beginning is 1 x 1011 granulocytes/kg in a volume of 15mL/kg. It is used  
once to twice in a day [68-70].  
4. Donor selection 
To select permanent blood donors, blood typing have to be performed. Donors should be 
healthy young adults. They undergo routine physical check up and hematology and clinical 
chemistry evaluations are done. They should never taken a blood transfusion and should be 
free of blood parasites and other infectious diseases [1]. 
Nulliparous and spayed female dog and cat donors have to be chosen. Blood have be 
collected via jugular venipuncture aseptically. Acepromazine interferes with platelet 
function. Because of this donors should not be sedated with it [1]. 
Every 3 to 4 weeks, dogs can donate between 13 and 17 ml of blood per kilogram of body 
weight. Features of donors sould include well nourished, supplemented with oral iron, bled 
less than once per month to prevent iron deficiency, greater than 25 kg, and negative for 
antigens for DEAs 1.1, 1.2, 3, 5, and 7. Donors should not have heartworm disease, 
babesiosis, brucellosis, ehrlichiosis, and Rocky Mountain spotted fever. Donors have 
appropriate neck skin that allows easy entrance to the jugular vein, have a packed cell 
volume that is at least 0.40 L/L, have demonstrated a good temperament and be in good 
physical condition, have no past time history of transfusion or pregnancy, and have got 
sufficient levels of von Willebrand factor (vWF) [1, 3].  
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The ideal feline blood donors should be healthy, indoor-only cats with an agreeable 
temperament for easy handling and restraint. Owned pet cats should be donate maximum 
once every 2 months [43]. The features of feline donor sould be as follows; weigh more than 
4.5 kg, have a packed cell volume that is at least 0.35 L/L, have demonstrated a good 
temperament, and be in good physical condition [3]. Donor cats can donate between 10 and 
12 ml/kg. Adult healthy cats can donate 50 ml every weeks. Donors have to be type A. Type 
B donors may be demanded depending on breed prevalence and geography. Feline 
leukemia virus, feline immunodeficiency virus (FIV), feline infectious peritonitis, heartworm 
disease, and Hemobartonella sp have to be excluded in donor cats [1]. 
For appropriate care of donors some processes needed. These are current vaccinations, if 
there is contact with new animals every 6 mo fecal floatation, monitorization of hemogram 
every year, analysing clinical chemistry, screening for infectious diseases and in the dog 
preventative heartworm therapy in areas where it is necessary. When blood collection is 
taken the donor's weight, temperature, and packed cell volume have to be analysed [3, 71]. 
PCV or Hb are measured by taking a blood sample.  Preferentially cats with a PCV of 30–
35% are used but cats with low–normal PCVs should not be used [43].  
In the cat, blood can be taken by using a 19- to 20 gauge needle or butterfly into a syringe via 
jugular vein venipuncture. The region over the jugular vein is clipped and prepared 
aseptically and sedation is administered. It is prefered to use a 1:1 combination of ketamine 
100 mg/ml and midazolam 5 mg/ml. It is made up in a small syringe and given 
intravenously up to a maximum dose of 5 mg/kg ketamine (0.1 ml/kg of combination). 
Syringe consists of either ACD, CPD, or CPDA- 1 (1 mL/9 mL of blood), or heparin (5 
units/mL of blood). Before a preservative solution is used it can be placed in a small blood 
bag. To access the jugular vein a 19-21G butterfly needle is used. The blood is collected over 
a total of 10 15 mins. At once a maximum of 10-12 ml/kg blood can be donated. Isotonic 
crystalloid fluid therapy post-donation at a rate of 60 ml/h for 3 h is given to the cat [3, 43]. 
5. Administration 
Precaution is necessary to prevent damage of the blood product and harm to recipient. 
Blood typing or crossmatching have to be carried out to provide compatibility before RBC 
transfusion [41].  
Transfusions of red blood cell should be administered through a filter. The filter is arranged 
to remove clots and particles which are potentially harmful to the patient. Blood infusion 
sets have in-line filters. These filters trap large cells, cellular debris, and coagulated proteins. 
The pore size range from 170µm to 260µm. A filter may be used to administer 2-4 units of 
blood to a patient or for a maximum time limit of 4 hours according to human blood 
banking standards. High protein concentration at the filter surface and room temperature 
conditions promote proliferation of any contaminating microorganisms. The rate of flow 
slowed down by accumulated material. After 5 days or more of refrigerated storage 
constituted microaggregates composed of degenerating platelets, white blood cells (WBCs), 
and fibrin strands in blood. They are removed by other blood filters with a pore size of 20-40 
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Jim. For transfusions of RBCs primarily microaggregate filters are designed. In 
administering small volumes of blood (<50 mL WB or <25mL pRBCs) to cats and small dogs 
a pediatric micro-aggregate blood filter (18 um pore size, priming space <lmL) is especially 
helpful. Because of a progressive decrease in pore size due to increased blood filtered larger 
volumes of blood administration can result in hemolysis [41]. 
If plasma is taken from blood preservative solutions can be put in. Blood preservative 
solutions are dextrose, adenine, mannitol, and the sodium chloride. They are necessary for 
RBCs to carry on their energy metabolism and viability during storage [3]. Canine pRBCs 
stored in a RBC preservative can be applied directly. Other pRBC products have to be 
diluted by putting 10mL of saline feline pRBCs or 100mL of saline to the blood bag so that 
the viscosity of the donor blood decreased [41]. 
In the dog, if sedation is needed, butorphanol (0.1 mg/kg BW, IV) is generally used for 
sedation. But acepromazine should not be used because it may cause platelet function 
disturbance [72]. In the cat, ketamin may be used 2 to 4 mg/kg BW, IV for sedation. In 
addition to ketamin is very successful when it is used together with 0.1 to 0.2 mg/kg BW 
diazepam [3]. Also combinations of ketamine hydrochloride, midazolam and butorphanol 
tartrate, or mask administration of sevoflurane can be used [73, 74]. 
Generally, intravenous administration is used for RBC transfusions. In addition  
intraosseous administration is a perfect alternative. Peripheral veins may be preferred to 
central veins because of an increased bleeding predisposition [41].  
Blood is administered through administration sets containing 0.9% saline intravenously. 
Contraindications include hypotonic saline, 5% dextrose in water and lactated Ringer's 
solution. Cardiac arrest may be caused by injection of undiluted citrate containing 
anticoagulants [1]. 
Using a syringe driver or by hand the transfusion should begin slowly at 0.25 ml/kg/h. If no 
adverse affects are encountered after the first 30–60 mins of administration the rate can be 
increased. Due to the urgency of the requirement for whole blood and any underlying 
concurrent disease the rate of administration can vary [75].  
With a PCV of 20%, dogs and cats with chronic anemia can be cardiovascularly stable [76]. 
Conversely in patients with an acute onset of anemia and continuing blood loss or 
hemolysis, transfusion to a higher PCV is necessary for stabilization. Generally 
administration of 2mL/kg of WB or lmL/ kg of pRBCs will increase the patient's PCV by 1% 
if there is no continuing hemorrhage or hemolysis [41]. 
Patient's overall condition determine the rate of blood administration. The maximum rate of 
transfusion is 10-20mL/ kg/h in normovolemic anemic patients, to avoid circulatory 
overload [41]. 
To provide blood volume again fluid therapy with crystalloids or colloids is necessary.  If 
the patient's total blood volume do not decrease under 20% this is usually enough for losses. 
If losses are more than 20% whole blood or packed red cell transfusion is used. Between 20% 
and 50% of blood volume losses are treated by crystalloids and packed RBCs [3, 77]. 
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Blood components like cryoprecipitate and platelet-rich plasma are used infrequently. 
Cryoprecipitate contains vWF, factors VIII, XIII, fibrinogen, and fibronectin. In vWF-
deficient patients cryoprecipitate is recommended particularly when surgery is planned or 
patient affected by blood loss. Bleeding hemophilia A patients, or patients having hypo or 
dysfibrinogenemia are the other indications for choosing it [3, 78].  
Sometimes platelet-rich plasma is used in veterinary practice. In small-sized animals it is 
more useful because in larger dogs it is difficult to gain enough volume and management of 
platelet count. An alternative to platelet-rich plasma are frozen platelet concentrates [79]. 
For expansion of plasma volume, different types of colloids as dextrans and hetastarch are 
used as alternatives to blood products. Altering hemostasis is one of the problems of 
dextrans and hetastarch. Oxyglobin is a hemoglobin-based oxygen carrier. It is approved for 
use in the dog in 1998. In emergency situations it is used instead of blood products when 
there is limited time for preparing it or performing compatibility testing [3, 80].  
In clinical signs of anaemia and as a therapy for carbon monoxide poisoning oxyglobin is 
used in cats. Because it is a potent colloid (colloid osmotic pressure 43 mmHg), the main risk 
associated with administration is volume overload. In patients with normovolaemic 
anaemia conservative administration rates are needed such as as low as 0.2-0.4 ml/kg/h and 
to a maximum of 1 ml/kg/h. Careful monitorization of patients with paying particular 
attention to their heart and respiratory rate is recommended [81, 82].  
A recent study described the clinical outcome in dogs experiencing massive transfusion. 
Also this study documented predictable changes in electrolytes and coagulation status. 
Massive transfusion is different from usual transfusions in terms of volume and rate of 
blood transfusion and blood components administered. Transfusion of a volume of whole 
blood or blood components has been described as massive transfusion. The administrated 
blood is greater than the patient's predicted blood volume within a 24-hour period or 
arranged as replacement of half the patient's predicted blood volume in 3 hours. In a study, 
massive transfusion receiving dogs were investigated and in this study the mean volumes of 
pRBCs was 66.5mL/kg and FFP was 22.2mL/kg. As a result of this mean plasma, RBC ratio 
was 1:3. After transfusion clinicopathologic changes consists of electrolytes disturbances, 
dilutional coagulopathy, ionized hypocalcemia and hypomagnesemia and progressive 
thrombocytopenia and prolongation of prothrombin and activated partial thromboplastin 
times [41, 83].  
6. Preparations used for transfusions and blood transfusions indications 
The gold standard approach is that the donor and recipient are cross-matched before 
administration. Administration is maintained mainly intravascular with the use of 
peripheral or centrally placed catheter. Also intraosseous catheters can be used to 
administer all blood products. It is useful in collapsed neonatal patients where vascular 
access is difficult [43, 75, 84]. 
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In acute hemorrhage, anemia, decreased red cell mass, severe methaemoglobinaemia, 
paracetamol toxicity, chronic non-regenerative anaemia, coagulation disorders, and 
thrombocytopenia fresh whole blood is used [1, 45].  
The reason of anaemia in cats requiring transfusion are haemorrhage and primary immune-
mediated haemolytic anaemia. Hemorrhage is caused as a result of peri- or postoperative 
bleeding, trauma, gastrointestinal bleeding, abdominal neoplasia, primary immune-
mediated thrombocytopenia and coagulopathies [85, 86, 87]. Also in a number of infectious 
diseases anaemia is reported such as especially feline immuno-deficiency virus (FIV) and 
feline leukaemia virus (FeLV) infections, and feline infectious peritonitis [88, 89]. Other 
infectious diseases which cause anemia are Ehrlichia species, Bartonella species, 
Haemoplasmas (Mycoplasma haemofelis, ‘Candidatus Mycoplasma haemominutum’ 
and ‘Candidatus Mycoplasma turicensis’), Anaplasma phagocytophilum, Neorickettsia 
risticii, Cytauxzoon felis and Rickettsia felis have additionally been associated with 
anaemia [43, 90]. 
The indication of whole blood is in a patient whom needed several blood components or has 
acutely lost more than 50% of its total blood volume. When 50% of total blood volume is lost 
oxygen carrying capacity and oncotic activity should be recovered. In anemia, stored whole 
blood is used. For anemic animals packed erythrocytes especially those with volume 
overload are prefered. For tissue reoxygenation the transfusion of packed RBCs are used. 
They are also useful for normovolemic, anemic patient. Before administration, to dilute any 
potentially damaging antibodies these erythrocytes can be washed with saline. Refrigerated 
whole blood should be warmed to room temperature. Before administration it sould be 
gently agitated to resuspend the red blood cells.  Infusion rate is limited by colder blood 
which has a higher viscosity [3, 41, 91].  
The usage of transfusion of fresh-frozen or stored-frozen plasma (FFP) are as follows; lack of 
coagulation factors associated with hepatic insufficiency, disseminated intravascular 
coagulation (DIC), vitamin K deficiency, rodenticide toxicosis, liver insufficiency, biliary 
tract obstruction, sepsis/multiple organ dysfunction syndrome, pancreatitis, 
hypoalbuminemia, and DIC without associated laboratoryproven coagulopathy, 
malassimilation syndrome, chronic antibiotic use, a need for plasma volume expansion, or a 
massive blood loss within a few hours. Other It is also used in congenital or a hereditary 
deficiency in coagulation factors (i.e hemophilia A, B, or von Willebrand's disease and 
hypoproteinemia), [1, 3, 39]. Plasma (FP or FFP) is used especially in the emergency 
conditions like excessive protein loss such as enteropathy, nephropathy, exudative 
dermatitis or inadequate intake. It is not appropriate for using as long-term source of 
protein in these patients [3, 92]. In cats, reactions have not been reported following 
transfusions of FFP [46]. 
The collection and re-transfusion of the cat’s own blood is called autotransfusion. It is a 
useful technique in an emergency situation. It can be obtained when animals bleed into 
body cavities. It should not be used if the blood is contaminated with urine, bacteria or bile. 
Blood is collected from the body cavity in a sterile manner. After that it re-transfused into 
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the patient through an appropriate fitler. To prevent clotting anticoagulant like acid citrate 
dextrose should be included at a ratio of 1:7 [39, 43]. 
7. Transfusions reactions  
The indication of transfusion reactions can be immunologic or nonimmunologic. They can 
be immediate or delayed. Antibodies to surface antigens of transfused erythrocytes cause 
immune-mediated hemolytic reactions. According to surface antigens canine blood is 
grouped. For six of these antigens typing is available. Except DEA 4, canine universal donor 
is negative for all dog erythrocyte antigens (DEAs). Universal donors should be examined. If 
other donors are known to be compatible with the recipient they can be also used. Acute 
hypersensitivities mediated by IgE antibodies are one of the possible immunologic reaction. 
The other can be leukocyte or platelet sensitivity caused by recipient antibodies to the 
donor's white cells or platelets. The mechanisms of nonimmunologic reactions are various. 
According to the specific reaction the type and severity of clinical signs vary [17] Adverse 
reaction occurs in 2 types. First one is immediate reaction and following transfusion it 
occurs within 1 to 2 h. Second is delayed reaction and it may begin within days, months, or 
years later [17]. Adverse reaction varies from mild (fever) to severe (death). Transfusion 
reactions can be acute or delayed. In animals receiving incompatible transfusions, acute 
intravascular hemolysis with hemoglobinemia and hemoglobinuria may be seen. Acute 
hemolytic reaction is the most serious transfusion reaction that can be prevented. It is an 
immunological reaction and it happens when circulating natural or acquired antibodies 
towards donor erythrocytic antigens are given. Hemoglobinuria, vasoconstriction, renal 
ischemia occur due to intravascular hemolysis. Intravascular hemolysis determine clinical 
signs. Disseminated intravascular coagulopathy (DIC) can be caused by release of 
thromboplastic substances. Secondary to the release of vasoactive substances, hypotension 
and shock can ocur. Also acute renal failure and death can develop. After transfusion a 
decrease in hematocrit between 2 days and 2 weeks resulted in suspicion of delayed 
hemolysis. As a result of extravascular hemolysis, hyperbilirubinemia and bilirubinuria may 
occur. In dogs clinical signs are as follows: fever, tachycardia or bradycardia, hypotension, 
dyspnea, cyanosis, excessive salivation, tearing, urination, defecation, vomiting, collapse, 
opisthotonos, cardiac arrest, hemoglobinemia, and hemoglobinuria. When an acute 
hemolytic reaction occured transfusion sould be interrupted at once and shock should be 
treated. Also blood product being used sould be checked out and the steps that led to the 
transfusion sould be examined [1, 3, 17, 93].  
To detect transfusion reactions earlier requires careful evaluation of patient's behavior, vital 
signs, and perfusion before, during, and after a RBC transfusion. Pre- and post-transfusion 
measurement of PCV and total solids for example instantly and at 24 hours are needed. Also 
evaluation of the plasma and urine for the presence of Hgb is done [41].  
In the dog the acute hemolytic reaction is rare because in this species naturally occurring 
anti-erythrocytic antibodies prevalence is low [3]. Alloantibodies against the common canine 
erythrocyte antigens 1.1 and 1.2 do not exist in dogs. As a result of this generally first 
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transfusion can be safely given without regard for donor blood type. Thus the recipient can 
be sensitized to immunogenic antigens (i.e 1.1, 1.2, 7, and others). On first transfusion it can 
cause shortened survival times of the transfused cells. Subsequent predisposition to severe 
transfusion reaction can develop. DEA 1.1 which is the strongest antigen in dogs, leads to 
the most severe transfusion reaction [1]. In the second transfusion especially when DEA-1 
type blood is applied twice to a DEA- 1-negative dog there is more risk [3].  
In cats receiving typed or crossmatched transfusions low rates of transfusion reactions have 
been indicated. Transfusions with whole blood or packed red blood cells transfusion reactions 
were reported [45]. But transfusions with FFP no reactions have been reported in cats [46].  
Initial or subsequent AB-mismatched transfusions in cats can cause acute hemolytic 
incompatibility reactions. Erythrocytes are destroyed immediately in cats because of 
alloantibodies. On the contrary in dogs, delayed transfusion reactions are more often occur. 
A type B transfusion to type A cat causes mild signs. In this situation shortened erythrocyte 
survival can occur. This causes ineffective therapy. Acute hemolytic transfusion reaction 
with massive intravascular hemolysis with serious clinical signs occurs in type A 
transfusion to a type B cat. These symptoms may occur even if it is the first transfusion. 
Type AB or A blood can be received by type AB cats safely [1, 94].  
The transfusion should be stopped immediately if a transfusion reaction is suspected. The 
recipient sould be monitored continually for follow up. The most severe is acute haemolytic 
transfusion reactions developing as a result of naturally occurring alloantibodies [32]. 
Clinical signs are restlessness, vocalisation, tachypnoea, bradycardia, tachycardia, 
hypotension and hypertension. Pyrexia is seen frequently as a result of reactions to donor 
leukocytes, platelets and plasma proteins. As a result of binding by citrate, there is potential 
for hypocalcaemia when administering large volumes of blood products. Thus, if the patient 
is showing clinical signs of hypocalcaemia calcium should be measured [38, 43]. 
The next hour after transfusion nonhemolytic fever can ocur as adverse reactions. If 
contaminated blood products applied by mistake, fever may occur in an acute hemolytic 
reaction in association with septicemia. Vomiting or diarrhea can be seen after plasma 
administration. Rarely urticaria may cause trouble to patient. It can be treated with 
antihistamines, with or without glucocorticosteroids. If whole blood is administered with 
rapid administration of a large volume of blood component to normovolemic cats or small-
sized dogs hypervolemia can be observed. Hypervolemia can result in pulmonary edema. 
Cough, tachypnea, dyspnea, or cyanosis can occur due to hypervolemia. Treatment can be 
done by stopping the transfusion, administering diuretics (furosemide) to reduce 
pulmonary edema, and providing oxygen support [3,72, 93]. 
The recipient should be carefully examined before the procedure. Its heart rate, respiratory 
rate, mucous membrane colour, capillary refill time and temperature sould be recorded. 
Also the PCV and total plasma protein should be recorded [43, 51] . 
Delayed adverse transfusion reactions are consist of delayed hemolytic reaction, 
transmission of infectious disease, and posttransfusion purpura. Posttransfusion purpura 
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has been reported in the dog. It is characterized by the appearance of severe 
thrombocytopenia in the week following a second transfusion. [3, 95, 96].  
Anemia, regardless of  underlying cause, is troublesome for clinicians in respect to 
stabilising and supporting the patient. The survival rate of all reasons for a transfusion is 
84% in the first 24 h. It is 75% for blood loss anaemia and 49.6% for ineffective erythropoeisis 
at 10 days [43, 97].  
8. Cross-Matching blood 
The incompatibilities between the donor’s red blood cells and recipient’s plasma are 
identified by major cross-match. The incompatibilities between the donor’s plasma and 
recipient’s red blood cells is identified by a minor cross-match [43]. 
Cross-Matching usually is identified as either ‘‘major’’ or ‘‘minor’’ cross-matches. A major 
cross-match include putting patient serum into donor cells and determine the presence of 
agglutinating and/or hemolytic antibodies in the patient aganist the donor antigens. The 
principle of this test is hemolytic or agglutinating reaction. In this test the reagent or 
antibody reacts with the RBCs. Serological discordance between a candidate donor and the 
patient is identified by the crossmatching. It does not determine the blood group [3]. A 
positive in vitro reaction is caused by the presence of antibodies. In patients that had no 
antibodies at the time of transfusion, a mild reaction can be seen in 4 to 14 days after 
mismatched transfusions. When blood is transfused to a patient in which antibodies are 
already present, a severe reaction occurs. This antibody can be developed by either naturally 
occurring or as a result of a previous mismatched transfusion. Furthermore, high 
concentrations of antibodies can be caused by isosensitization from transplacental 
immunization. In dogs that have received transfusions before, a crossmatch should always 
be performed. A minor cross-match include putting donor serum into patient erythrocytes. 
This step is not necessary for the donor whom previously tested negative for antibodies. 
Transfusing packed or washed erythrocytes rather than whole blood can prevent 
administration of antibodies in donor blood against patient erythrocytes [1]. 
Before transfusion the reason of analysis with these methods are to prevent acute hemolytic 
reaction due to transfusion, to provide optimal lifetime of the transfused RBCs, to prevent 
next discordant blood transfusions and to prevent neonatal isoerythrolysis [3].  
Because there are blood types that have not been described and it is not possible to type for 
Mik it is recommended that cross-matching is performed before any transfusion. If the 
recipient has received a transfusion before more than 4 days cross-matching should be 
performed [98]. 
9. Principles of blood transfusion in horses 
Horses have eight RBC groups or systems: A, C, D, K, P, Q, U, and T. The first seven 
systems are recognized by the International Society of Animal Blood Grouping Research. 
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Blood-typing antiserum is not readily available for horses. Because of this to identify 
suitable donors equine blood-group testing can be performed by only few diagnostic 
laboratories. Over 30 different factors have been identified within these seven equine 
systems.  Experimentally many more systems have been identified [99, 100]. Red cell 
antigens Ca, Aa, and Qa are play an important role in transfusion reactions and neonatal 
isoerythrolysis. There is no universal equine blood donor. Because of this to prevent 
inadvertent sensitization of brood mares against the two most common alloantigens (Aa and 
Qa) involved in neonatal isoerythrolysis, the preferred donor should be negative for factors 
Aa, Qa, and Ca [100, 101]. Aa and Qa alloantigens are most immunogenic, and most 
neonatal isoerythrolysis cases are associated with anti-Aa or Qa antibodies. The horse is 
clinically relevant for blood group incompatibilities. It is the only livestock species for this 
situation. Blood group antibodies can laed to transfusion reactions or NI and can be found 
in horses either ‘‘naturally’’ or as a result of a blood group incompatible pregnancy [2]. A 
donkey RBC antigen that has not been found in the horse has been identified, it is unique to 
the donkey and the mule [1]. 
In horses, requirement of blood transfusion include correction of anemia arising from acute 
blood loss secondary to trauma, surgical complications, ruptured uterine artery, guttural 
pouch mycosis, and neonatal isoerythrolysis [99, 102]. 
Generally, whole blood transfusions are applied to horses that have acute blood loss caused 
by trauma, surgery, or some other conditions like splenic rupture or uterine artery 
hemorrhage. The transfusion recovers blood volume and oxygen-carrying capacity in cases 
of blood loss. There is no certain indicative variables for the beginning of transfusion so that 
physical examination and clinicopathologic parameters should be used to make the 
transfusion decision. In cases of acute hemorrhage one sould remember that the packed cell 
volume (PCV) may be normal for up to 12 hours because of the time required for fluid 
redistribution and the effects of splenic contraction. As the horse is rehydrated with 
intravenous fluids, serial monitoring of PCV and total protein (TP) can estimate the amount 
of blood loss. The transfusion decision is made by suspection of large volume blood loss, 
together with tachycardia, tachypnea, pale mucous membranes, lethargy, and decreasing 
TP. During an acute bleeding episode when the PCV fall under 20%, blood transfusion is 
probably required. In acute severe cases, transfusion may be required before there is a 
significant fall in PCV. PVC shows the need for beginning of transfusion in chronic anemia 
better whereas in acute hemorrhage, with transfusions proposed for horses with 
demonstration of tissue hypoxia and a PCV less than 10-12% [103, 104].   
Blood is collected and stored in glass bottles containing acid–citrate–dextrose (ACD). The 
method traditionally used for collecting blood from donor horses. Glass bottles containing 
ACD are easy and suitable for rapid vacuum blood draw. Because of this they are 
recommended for equine whole-blood collection. For equine whole blood the optimal storage 
method is commercial citrate–phosphate–dextrose with adenine (CPDA-1) bags [105, 106]. 
Packed RBCs (pRBCs) are specified for normovolemic anemia (i.e neonatal isoerythrolysis, 
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lactate and oxygen extraction are useful in chronic or hemolytic anemia cases. In horses, 
disseminated intravascular coagulation, clotting factor deficiency, hypoalbuminemia, 
decreased colloid oncotic pressure, and failure of transfer of passive immunity (FPT) are 
treated by plasma [104].  
Colloid is usually used in patients with a total protein less than 4.0g/dL or serum albumin 
concentration less than 2.0g/dL. When there is oncotic pressure less than 14 mmHg, clinical 
symptoms like ventral edema, and conditions which increase microvascular permeability 
like sepsis are other indications for colloid usage [104]. 
According to plasma obtained by plasmapheresis and centrifugation preparations,  plasma 
prepared by gravity sedimentation contains greater numbers of erythrocytes and leucocytes. 
The risk of a transfusion reaction can be increased by these cells. During storage leukocytes 
can degranulate and fragment and release pyrogens and proinflammatory substances [107, 
108, 112]. 
Multiple hyperimmune plasma products are avaible with bacterial or viral specific 
antibodies. For the treatment of equine endotoxemia, the efficacy of E. coli (J5) and 
Salmonella tiyphiimiriuni hyperimmune plasma has proved to be useful in some reports; in 
contrast, there are some reports which disapprove the utility of such products. For the 
protection of R. equi, the use of Rhodococcus equi hyperimmune plasma has also been 
controversial. For treatment of specific disease additional plasma products like botulism 
antitoxin, West Nile virus antibody, and Streptococcus equi antibody are usable. In general 
equine practice plasma is administered to neonates to provide protective immunoglobulins. 
Protective immunoglobulins are used for treatment of failure of transfer of passive 
immunity or prophylaxis against Rhodococcus equi. Also, the albumin content of the 
plasma used as a colloid for circulatory volume support and in the treatment of protein-
losing enteropathies. In horses heritable and acquired coagulopathies can occur. Specific 
coagulation factors are not available for supplementation. Also indications include 
coagulopathies, protein-losing nephropathy and protein loss through third spacing into a 
body cavity (occurring with peritonitis or pleuritis) [104, 109-113]. 
Fresh frozen plasma must be separated and frozen within 8 hours of blood collection. Then 
it can be colder at -18 °C and stored for up to 1 year. Frozen plasma is considered as plasma 
separated any time after 8 hours of blood storage [112, 114, 115].  
9.1. Blood donor selection 
Healthy, young gelding weighing at least 500 kg is the ideal equine blood donor. Donor 
horses should be performed current vaccinations. To prevent from equine infectious anemia 
donors should be tested each year. RBC antigens Aa and Qa are the most immunogenic 
antigens. Because of this in the ideal donor, the Aa and Qa alloantigens should be absent. 
There are breed-specific blood factor frequencies. Thus a donor of the same breed as the 
recipient, particularly when blood typing is absent may be preferable. Horses that have 
taken blood or plasma transfusions and mares that have had foals are not appropriate as 
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donors. Because they have a higher risk of carrying RBC alloantibodies. Donkeys have a 
RBC antigen known as "donkey factor". Horses do not have this antigen. Thus donkeys or 
mules should not be used as donors for horses because horses can develop anti-donkey 
factor antibodies if transfusion takes place [1, 104, 116]. 
An immediate blood transfusion can be applied for the first time in an emergency situation 
with a very minor risk of serious transfusion reaction. Horses can develop alloantibodies 
within 1 week of transfusion. Thus blood typing and crossmatching are recommended 
before a second transfusion is given. A second blood transfusion may be given confidently 
without a blood crossmatch within 2-3 days of the first transfusion. Blood typing and 
alloantibody screening can be used for the transfusion needed patient to find the most 
suitable donor horse. Blood typing and antibody screening before initial transfusion are 
more important for horses. Because subsequent blood transfusions are anticipated and if 
sensitized to other blood group factors broodmares may produce foals with neonatal 
isoerythrolysis (NI). For detection of equine RBC antigens Ca and Aa, a rapid agglutination 
method has been developed. It can be more suitable for pretransfusion testing [99, 103, 104]. 
9.2. Collection techniques  
Blood is collected from the jugular vein of the donor horse. For this purpose two way used; 
direct needle cannulation or catheteri-zation. When a large volume of blood is required, a 10 
or 12 gauge catheter is recommended. A 14 gauge catheter is also sufficient. Plastic bags and 
vacum-collection glass bottles in sizes ranging from 450 mL to 2 L are suitable for blood 
accumulation. Anticoagulation with 3.2% sodium citrate is enough when blood is received 
for immediate transfusion. In saline-adenine-glucose-mannitol solution red blood cell 
concentrates stored and they can be used for transfusion for up to 35 days after blood 
accumulation. Equine blood storage condition resemble to canine and human blood storage 
condition. According to both in vitro tests and human parameters after 35 days of storage 
equine erythrocytes remain appropriate for transfusion. Fresh frozen plasma is obtained by 
separation of erythrocytes and plasma. Both of them can be used alone. RBC survival 
evaluation sould be doen in vivo [104, 117].  
To allow separation of red blood cells by gravity sedimentation the blood is stored in a 
refrigerator at 5 °C for 48 hours in an upright position. Then the plasma is decanted into a 
sterile 3-L bag with sterile plastic connecting tubing using gravity. 3-L bags containes a 
constant weight of plasma (3.4 kg). The red cell fraction is thrown out. The plasma bags are 
sealed, labeled with the horse’s name and the date of decantation. They are stored at -20 °C 
until needed for plasma transfusion [112, 118]. 
9.3. Administration 
In acute blood loss cases, PCV is usually impractical for estimation of volume to be 
transfused because it does not exactly indicate blood loss. Instead of this the volume of 
blood needed are predicted by estimation of blood loss and evaluation of clinical 
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parameters. Fluid shifts will replace much of the circulating volume so between 25% and 
50% of the total blood lost should be replaced by transfusion. Pay attention sould be give to 
that up to 75% of RBCs lost into a body cavity like hemoperitoneum are within 24-72 hours 
autotransfused back into circulation. Thus in cases of intracavitary hemorrhage lower 
percentages of blood volume replacement can be needed. To remove small clots and fibrin 
blood and plasma products should be given with an in-line filter [104, 119]. 
9.4. Adverse reactions 
Blood should be given at a rate of approximately 0.3mL/ kg over the first 10-20 minutes for 
monitoring the transfusion reactions. Heart rate, body temperature, and respiratory rate 
sould be monitored. Additionally horses have to be monitored for signs of muscle 
fasciculation, piloerection, and urticaria. Urticaria, hemolysis, pruritis, edema, tachycardia, 
tachypnea, pyrexia, colic, changes in mentation and acute anaphylactic reactions are adverse 
reactions indicated in horses taking blood transfusions. The rate of adverse reaction to WB 
transfusion has been reported as 16% which are mild urticarial reactions and worsening 
hemolysis. Also 1 of 44 horses (2%) exhibit a fatal anaphylactic reaction [103, 113].  
Transfusion reactions may vary from mild urticarial reactions to anaphylaxis. They are 
divided into immunogenic and nonimmunogenic reactions. Immunogenic reactions include 
anaphylaxis, hemolysis, fever, hives, acute lung injury, posttransfusion purpura, 
immunosuppression, and neonatal isoerythrolysis. Nonimmunogenic reactions include 
circulatory overload, bacterial contamination, citrate toxicity, coagulopathy, 
hyperammonemia, and transmission of disease. In horses that have received fresh frozen 
plasma serum hepatitis has been observed [52, 93, 112, 120].  
In a second plasma or blood transfusion there exists risk for severe adverse reactions in 
dogs. Also there is a risk of development of neonatal isoerythrolysis in gravid mares. The 
risk is much more in whole blood transfusions [26, 33, 112]. 
In horses suffered from normovolemic anemia polymerized ultrapurified bovine 
hemoglobin (PUBH)  improves hemodynamics and oxygen transport parameters. During 
infusion to be informed about any adverse reactions patients should be monitored closely. 
Intense pruritus, tachycardia, and tachypnea can be resolved shortly after stopping the 
infusion [121]. 
10. Principles of and indications for blood transfusion in ruminants and 
camelids 
Eleven blood groups have been classified in cattle. The greatest clinical relevance is in 
groups B and J. The B group is extremely complex, thus closely matched transfusions are 
very difficult. Newborn calves do not have the J antigen. During the first six months of life 
they generally acquire it. Cows can be sensitized to erythrocyte antigens by vaccinations of 
blood origin like some anaplasmosis and babesiosis vaccines. As a result of this neonatal 
isoerythrolysis in subsequent calves occur. [1].  
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Seven blood groups have been classified in sheep. The B group in these animals is resemble 
to the B group in cattle, and the R group is resemble to the J group in cattle. For example, 
antigens are soluble and soluble antigens passively absorbed to erythrocytes. In the goat, 
five blood groups are identified which resemble to those of sheep [1]. 
Blood group A–O expression is affected by 16 porcine blood groups and the S gene. 
Carbohydrate antigens like AO blood group antigens and minor histocompatibility antigens 
can be important targets for the immune response to transplanted organs or tissues. These 
antigens remain an unknown and untested variable in many transplant studies using pigs. 
Depending, on work performed in some Europian country pig blood groups developed and 
expanded largely. The source of blood typing reagents is especially from isoimmune sera. 
Most antibodies behave as agglutinins and a few as hemolysins. Internationally sixteen 
genetic systems are recognized [2, 122-124]. 
In two domestic South American camelids, Ilama and alpaca, our knowledge is little about 
group variation. Six blood groups factors were identified (e.g A, B, C, D, E and F) . from iso- 
and heteroimmune sera constituted for these animals [2]. 
In ruminants and camelids indications for WB and plasma transfusion are similar to horses. 
Chronic anemia may be a more common problem in ruminants. Gastrointestinal parasites, 
particularly Haemonchus contains, and ectoparasites (e.g. Haematopinus spp. and 
Linognathus spp.) are causes of chronic blood loss anemia, and iron-deficiency anemia. 
These can affect neonatal calves [104, 121, 125].  
Studies with camelids and bovines has showed that the neonatal intestine can only 
successfully absorb colostral immunoglobulins for 12–24 hours postpartum. Passive transfer 
(FPT) is failed in 19% to 24% of neonatal camelids. A common indication for plasma 
transfusion in neonatal calves and crias is failure of transfer of passive immunity. 
Hyperimmune serum products are existing for subcutaneous and intramuscular dosing in 
ruminants. These are products with antibodies against E. coli, Pasturella, Aercanobacter 
pyogenes, Salmonella typhimurium and Clostridium [104, 126-129]. 
An integral component of neonatal camelid care is IV plasma transfusion. It is used for the 
purpose of antibody supplementation and fluid resuscitation in critical illness. Neonates are 
immunocompetent at birth but due to initial postpartum absorption of colostrum for passive 
acquisition of immunoglobulins (especially IgG) they are severely hypogammaglobulinemic 
[130, 131].  
In cattle, the first blood transfusion should usually be safe, regardless of the donor. J-
negative donor is ideal. Because agglutination reactions do not develop, routine 
crossmatching is not useful in ruminants. First transfusions are usually safe to apply 
without a blood cross-match but crossmatching is recommended when more than 48-72 
hours have passed away since the first blood transfusion. Blood donors should not have 
disease like bovine leukosis virus, anaplasmosis, and bovine viral diarrhea virus [104]. 
Total blood volume estimated in cattle is 80 mL/kg. From the donor animal up to 20-25% of 
total blood volume can be removed. Usually needle cannulation or jugular catheterization 
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used in this situation. Blood can be collected into bottles or bags using citrate anticoagulant 
(e.g CPDA-1) in equine transfusions [104]. 
Blood samples can be taken from the jugular vein in sheep. A 500 ml transfer bag system 
including a needle can use for the storage. These bags include 70 ml of CPDA-1-stabiliser. 
Then the blood should be put into four 150 ml transfer bags. These bags can be stored on a 
horizontal shaker. It shows the best preservation of platelet function. Also it can be used for 
the storage experiment consecutively [132]. 
Platelet count and aggregability of CPDA-1-stabilised ovine blood is kept most covenient at 
room temperature. It provides adequate haemostatic function for ex vivo experiments for 
one working day. In ovine blood functional loss and high percentage of platelets within 
aggregates can be observed at refrigerator temperature. This should be considered in blood 
transfusion in sheep [132].  
10.1. Administration and adverse reactions 
In order to monitor transfusion reactions blood should first be transported slowly. 
Ruminant blood type discordance result in primarily complement-mediated hemolysis. 
Volume overload should not be given. Also in neonates and small ruminants volume should 
carefully be given [104].  
Intestinal absorption of antibodies declines sharply within the first 24 hours postpartum. For 
treatment of crias with failure of passive transfer (FPT) IV or intraperitoneal administration 
of 20–40 mL/kg of camelid plasma is recommended. In compromised neonates requiring 
fluid resuscitation IV administration of plasma is generally preferred. It is used for the 
correction of FPT and colloid support. In foals during extensive plasma volume expansion 
careful monitoring is needed to prevent cardiopulmonary complications. Following IV 
plasma administration the cardiovascular and pulmonary effects of plasma volume 
expansion have not been specifically worked out in camelids. But in several species (i.e 
sheep and cat) plasma volume overexpansion depending on excessive IV fluid 
administration has been associated with reduced lung function and pulmonary edema 
formation in clinical and experimental settings. In addition according to measures in 
presumed hypovolemic human patients administration of colloids can induce a greater 
reduction in lung function than crystalloids [130, 133-137].  
Measurable plasma volume expansion and a concurrent reduction in pulmonary functional 
residual capacity (FRC) is caused by IV administration of 30 mL/kg camelid plasma to 
neonatal crias. In healthy neonatal crias administration of this quantity of plasma seems to 
be safe. But with underlying cardiopulmonary or systemic disease changes in lung volume 
associated with plasma administration could create risks for crias (131). 
Adverse effects of transfusing blood stored for prolonged periods in lamps is encountered 
more often in patients with reduced vascular nitric oxide levels because of endothelial 
dysfunction. These patients can benefit from transfusion of fresh PRBC if available. Also 
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inhaled nitric oxide supplementation can prevent pulmonary hypertension associated with 
transfusion of stored PRBC [138]. 
In previously untransfused pigs, hemolytic transfusion reactions do not appear to develop. 
But there have been two reports about adverse reactions in pigs undergoing liver 
transplants by the use of A–O incompatible transfusions. Pulmonary hypertension and 
decreased fibrinogen with an associated increase in fibrin degradation products occured in 
pigs that received A–O incompatible transfusions [139]. In a study, two pigs that 
administered A–O incompatible blood transfusions during liver transplants died because of 
disseminated intravascular coagulation (DIC), bleeding and progressive hypotension [140]. 
11. Conclusion 
Vital part of veterinary emergency and critical care medicine is transfusion medicine. It is 
also therapy of some disease of patient. Blood and blood products can be obtained through 
the purchase of blood products or donors. Potentially fatal adverse transfusion reactions risk 
is higher in cats than in dogs. Also, adverse transfusion reactions are very important for 
large animals. By using known donors and screening assays that permit detection of 
incompatibility of blood typing or crossmatching, the risk can be decreased in both species.  
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